3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Gastrointestinal
1
Dermatologic
1
Conditions
Skin Neoplasms
1
Melanoma
1
Interventions
pembrolizumab
81
Nivolumab
55
Ipilimumab
44
Cyclophosphamide
38
aldesleukin
26
Interleukin-2
25
fludarabine
17
Temozolomide
17
fludarabine phosphate
16
trametinib
11
dabrafenib
11
Radiotherapy
11
Biopsy
11
avelumab
10
Paclitaxel
9
spartalizumab
8
cemiplimab
8
Dacarbazine
8
Cisplatin
8
Bevacizumab
8
sargramostim
7
binimetinib
7
Fluorouracil
7
poly ICLC
6
lenvatinib
6
epacadostat
6
atezolizumab
6
Magnetic Resonance Spectroscopy
6
Granulocyte-Macrophage Colony-Stimulating Factor
6
montanide ISA 51
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
reolysin
×
Dermatologic
×
Clear all
NCT03282188
2018-05-04
REO13 Melanoma With of Without GM-CSF
University of Leeds
Phase 1/2
Withdrawn